On 27 May, the US Food and Drug Administration (FDA) approved San Diego-based Optimer Pharmaceuticals' Dificid (fidaxomicin), a new antibiotic for the treatment of Clostridium difficile-associated diarrhoea (CDAD).
Dificid is the first new therapy approved by the Agency for CDAD, a growing public health threat and a particular problem in hospitals and long-term care facilities, in almost 25...